Wattle Hill Capital

Wattle Hill invests in Australian and New Zealand companies with strong brands in consumer goods, agribusiness, and healthcare, then actively drives their expansion into China and other Asian markets. The thesis relies on the premium reputation of Australian products in Asia, particularly for food safety and health. Rather than generic growth equity, the firm specializes in cross-border market access as the primary value-creation lever. Albert Tse founded the firm specifically to execute this corridor strategy.

Albert Tse, the founder and CEO, is the central decision-maker. Tse previously held senior roles at Macquarie Group, and his professional network across Greater China forms the basis of the firm's deal-sourcing and portfolio-company distribution efforts. A small team of principals supports origination and due diligence, but the concentrated governance structure means investment committee authority rests firmly with the founder.

The firm originates deals primarily in Australia and New Zealand, targeting companies that can benefit from Asian market access. Wattle Hill has not publicly indicated a strategy of investing directly into Asian-domiciled companies. Its role is to serve as a bridge — taking equity stakes in ANZ businesses and using its operational expertise to unlock demand in China and Southeast Asia.

Deal flow originates primarily through Albert Tse's personal network, which spans Australian corporate advisory, Asian trade finance, and the diaspora business community. The firm's narrow thematic focus — ANZ-to-Asia consumer and health — means it competes less frequently in broad auction processes and more often in bilateral or lightly intermediated transactions where the cross-border angle deters generalist sponsors.